The advent of initial EGFR inhibitors such as gefitinib and erlotinib represented a pivotal advancement, presenting a promising prospect for individuals afflicted with EGFR-mutated NSCLC [12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.